Polarean Imaging plc Stock

Equities

POLX

GB00BF3DT583

Advanced Medical Equipment & Technology

Market Closed - London S.E. 11:35:12 2024-04-26 am EDT 5-day change 1st Jan Change
3.75 GBX -1.32% Intraday chart for Polarean Imaging plc -3.85% -40.00%
Sales 2023 * 800K Sales 2024 * 2M Capitalization 10.13M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 5.04 x
Net cash position 2023 * 6.1M Net Debt 2024 * 2.1M EV / Sales 2024 * 6.12 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 28
Yield 2023 *
-
Yield 2024 *
-
Free-Float 72.05%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.32%
1 week-3.85%
Current month-12.79%
1 month-16.67%
3 months-53.12%
6 months-51.61%
Current year-40.00%
More quotes
1 week
3.70
Extreme 3.7
4.00
1 month
3.70
Extreme 3.7
4.49
Current year
3.50
Extreme 3.5
8.50
1 year
3.50
Extreme 3.5
33.00
3 years
3.50
Extreme 3.5
113.00
5 years
3.50
Extreme 3.5
113.00
10 years
3.50
Extreme 3.5
113.00
More quotes
Managers TitleAgeSince
Founder - -
Chief Executive Officer 53 23-06-20
Chairman - -
Members of the board TitleAgeSince
Director of Finance/CFO 58 19-04-28
Director/Board Member 62 22-04-13
Director/Board Member 69 23-09-26
More insiders
Date Price Change Volume
24-04-26 3.75 -1.32% 514 850
24-04-25 3.8 -2.56% 161,416
24-04-24 3.9 +1.30% 1,137,701
24-04-23 3.85 -1.28% 543,831
24-04-22 3.9 0.00% 255,395

Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT

More quotes
Polarean Imaging PLC is a medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI). The Company and its subsidiary company operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. The Company’s technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. It operates in Canada, Germany, United Kingdom and United States. The Company’s subsidiary is Polarean, Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0475 USD
Average target price
0.547 USD
Spread / Average Target
+1,052.15%
Consensus

Chiffre d''affaires - Rate of surprise